Tilray | TRLY - Cash And Equivalent


Tilray reported $264.83M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Acasti Pharma USD 18.67M 1.81M Dec/2025
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Aurora Cannabis CAD 64.69M 8.33M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Canopy Growth CAD 364.68M 6.64M Mar/2026
Cronos Group USD 467.02M 354.84M Jun/2026
Dianthus Therapeutics USD 110.55M 517.12M Jun/2026
Divis Laboratories Ltd INR 1.28B 2.87B Mar/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Knight Therapeutics CAD 76.45M 5.43M Dec/2025
Moderna USD 1.72B 185M Jun/2026
Organigram Holdings CAD 4.29M 3.28M Mar/2026
Organon & Co USD 1.13B 16M Jun/2026
Revvity USD 1.02B 162.62M Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Tilray USD 264.83M 43.16M Jun/2025
Viatris USD 886.5M 917.7M Jun/2026
Xeris Pharmaceuticals USD 121.75M 10M Jun/2026
Zealand Pharma A/S 3.85B 727.54M Mar/2026